

***Fiscal Year 2020 Tuberous Sclerosis Complex Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Exploration – Hypothesis Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><b>W81XWH-20-TSCRP-EHDA</b></p>	<p>Investigators at all academic levels (or equivalent), including postdoctoral fellows</p>	<ul style="list-style-type: none"> <li>• Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field.</li> <li>• Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.</li> <li>• <b><i>Preliminary data not required.</i></b></li> <li>• Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>2</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$150,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> June 18, 2020 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> July 9, 2019 11:59 p.m. ET</p>
<p><b>Idea Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><b>W81XWH-20-TSCRP-IDA</b></p>	<p><b><i>Established Investigators:</i></b></p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p> <p><b><i>or</i></b></p> <p><b><i>New Investigators:</i></b></p> <p>Independent investigators at or below the level of Assistant Professor (or equivalent) <b>or</b> Established Investigators in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC</p>	<ul style="list-style-type: none"> <li>• Supports ideas that have the potential to yield high-impact findings and new avenues of investigation.</li> <li>• <b><i>Preliminary data expected.</i></b></li> <li>• Clinical trials not allowed.</li> <li>• <b><i>New Investigator Option</i></b> supports the continued development of promising independent investigators that are early in their faculty appointments <b>and/or</b> the transition of established investigators from other research fields into a career in the field of TSC research.</li> <li>• Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>3</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$450,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 18, 2020 5:00 p.m. ET</p> <p><b>Application:</b> July 9, 2020 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Translational Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><b>W81XWH-20-TSCRP-CTRA</b></p>	<p>Independent Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC.</li> <li>• Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest.</li> <li>• Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies.</li> <li>• Pilot clinical trials, including behavioral interventions are encouraged.</li> <li>• Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.</li> <li>• Preclinical studies may be appropriate but must include a clinical component.</li> <li>• Projects that are exploratory and/or strictly animal research will not be considered for funding.</li> <li>• <i>Preliminary data required.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>3</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$600,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 18, 2020 5:00 p.m. ET</p> <p><b>Application:</b> July 9, 2020 11:59 p.m. ET</p>